Introduction: Valproic acid (VPA) is a narrow therapeutic index drug widely prescribed for the treatment of epilepsy, psychiatric disorders, and migraine. First available as an enteric-coated immediate release formulation (IR), its fast absorption profile and short half-life motivated the development of extended-release formulations (ER) to reduce both daily administrations and pharmacokinetic peak-to-trough fluctuation (PTF). A […]
Prediction of multiple-dose relative bioavailability outcome for an extended release valproic acid formulation
January 10, 2021
Authors Alejandra Schiavo (1), Pietro Fagiolino (1), Marta Vázquez (1), Iñaki F. Trocóniz (2,3), Manuel Ibarra (1)
Affiliations (1) Department of Pharmaceutical Sciences. Faculty of Chemistry. Universidad de la República. Montevideo, Uruguay. (2) Pharmacometrics and Systems Pharmacology Research Unit, Department of Pharmaceutical Technology and Chemistry, School of Pharmacy and Nutrition, University of Navarra. Pamplona, Spain. (3) IdiSNA; Navarra Institute for Health Research, Pamplona, Spain.
Presentation type Poster
Presenters Alejandra Schiavo, Manuel Ibarra
Attachments
